Evidence map›Paper›PMID 31969123›Full record

ArticleBMC cancer2020

Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge.

Xiaoqi Zhou, Jifei Wang, Mimi Tang, Mengqi Huang, Ling Xu, Zhenpeng Peng, Zi-Ping Li, Shi-Ting Feng

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Xiaoqi ZhouDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Jifei WangDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Mimi TangDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Mengqi HuangDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Ling XuFaculty of Medicine and Dentistry, University of Western Australia, Perth, Australia.
Zhenpeng PengDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Zi-Ping LiDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. liziping163@163.com.
Shi-Ting FengDepartment of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. fengsht@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-0869-7290
Sun Yat-sen University · CNThe University of Western Australia · AU

Funding

National Key Research and Development Program of China 2017YFC0113402National Natural Science Foundation of China 81571750National Natural Science Foundation of China 81770645National Natural Science Foundation of China 81771908
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) with hilar bile duct tumor thrombus (HBDTT) often mimic hilar cholangiocarcinoma (hilar CC). The purpose of this study is to analyze the Computed Tomography (CT) characteristics of HCC with HBDTT and to identify imaging features to aid its differentiation from hilar CC on enhanced CT.

methodsWe retrospectively identified 58 cases with pathologically proved HCC with HBDTT between 2011 and 2018. Seventy-seven cases of pathologically proven hilar CCs were selected during the same period. The clinical features and CT findings of the two groups were reviewed and compared.

resultsHCC with HBDTTs are more commonly found in men (87.9% vs 63.6%, p = 0.001) with lower age of onset (49.84 vs 58.61 years; p < 0.001) in comparison to hilar CCs. Positive correlation were identified between HCC with HBDTTs and chronic HBV infection (72.4% vs 11.7%; p <  0.001), increased serum AFP (67.2% vs 1.3%; p <  0.001), CA19-9 level (58.6% vs 85.7%; p <  0.001) and CEA level (3.4% vs 29.9%; p = 0.001), parenchymal lesion with intraductal lesion (100% vs 18.2%; p <  0.001), washout during the portal venous phase (84.5% vs 6.5%; p <  0.001), thickened bile duct wall (8.6% vs 93.5%; p <  0.001), intrahepatic vascular embolus (44.8% vs 7.8%; p <  0.001), splenomegaly (34.5% vs 2.6%, p <  0.001). A scoring system consisting of the five parameters obtained from characteristics mentioned above was trialed. The sensitivity and specificity for diagnosing HCC with HBDTT were 96.39, 100 and 92.5% respectively when the total score was 2 or more.

conclusionsHCC with HBDTTs are often distinguishable from hilar CCs based on washout during portal venous phase without thickened bile duct wall. HBV infection and serum AFP level facilitate the differentiation.

Indexed as

AdultAgedAged, 80 and overBile Duct NeoplasmsCarcinoma, HepatocellularDiagnosis, DifferentialFemaleHumansKlatskin TumorLiver NeoplasmsMaleMiddle AgedResearch DesignRetrospective StudiesSensitivity and SpecificityThrombosisComputed tomographyHepatocellular carcinomaHilar bile duct tumor thrombusHilar cholangiocarcinoma

Identifiers

PMID31969123
PMCPMC6977349
OpenAlexW3012777960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.